EEG and Seizure Patterns Mapped in First Two Years of CDKL5 Disorder

Children with CDKL5 deficiency disorder develop a characteristic electroclinical picture within the first two years of life, and a new longitudinal analysis published in Neurology® maps how scalp EEG findings, seizure patterns, and developmental trajectories unfold together across that window.

CDKL5 deficiency disorder is a rare developmental and epileptic encephalopathy caused by pathogenic variants in the cyclin-dependent kinase-like 5 gene, located on the X chromosome. It predominantly affects girls. Affected infants typically present with seizures in the first months of life, and the new study addresses a gap that matters to every pediatric EEG reader: when do the EEG abnormalities appear, what do they look like at each stage, and how do they track with clinical development?

The investigators followed a cohort of children with genetically confirmed CDKL5 deficiency disorder through the first 24 months of life, analyzing serial scalp EEG recordings alongside documented seizure semiology and standardized developmental assessments. The longitudinal design is the study's strength. Cross-sectional EEG descriptions of this disorder exist, but the sequence of electrographic change — and its timing relative to seizure onset and developmental regression or plateau — has been harder to pin down.

The early EEG course in CDKL5 deficiency disorder has long been described as deceptively normal. That pattern is clinically important. Infants may present with frequent seizures — often abrupt-onset tonic or epileptic spasms — while the interictal scalp EEG still shows only mild or nonspecific background abnormalities, and frequently no epileptiform discharges. A normal or near-normal EEG in a infant with very early-onset, drug-resistant seizures should therefore raise suspicion for a genetic epileptic encephalopathy such as CDKL5 deficiency disorder rather than reassure the clinician. Prompt genetic testing, rather than prolonged repeat EEG monitoring alone, is the efficient diagnostic path in this scenario.

As the study's longitudinal data show, this early EEG quiescence gives way over the following months to a more clearly epileptic picture. With time, the interictal record typically develops background slowing, and epileptiform abnormalities become prominent. The hypsarrhythmia question is central here: children with CDKL5 deficiency disorder can transition into infantile spasms, and the EEG may evolve toward modified hypsarrhythmia or burst-suppression-like patterns during that phase. Distinguishing a true hypsarrhythmic transition from other encephalopathic patterns has direct treatment consequences, because infantile spasms in this population may respond to standard spasm therapies — hormonal treatment courses or vigabatrin — even when the broader seizure disorder remains drug-resistant.

For reading-room practice, the study's message is to date the EEG against the developmental timeline. The same montage that looked unremarkable at three months can look markedly abnormal at twelve. Serial comparison, not single-record interpretation, is what reveals the disorder's signature evolution. Pediatric electroencephalographers reviewing records from infants with suspected CDKL5 deficiency disorder should track background organization, the emergence and distribution of epileptiform discharges, and any shift toward hypsarrhythmia or discontinuity across serial studies.

The seizure data in the study reinforce what clinicians already recognize as one of the most refractory early-onset epilepsies. Seizure onset in CDKL5 deficiency disorder typically occurs within the first three to eight months of life, and the seizures rarely remit with conventional antiseizure medication. Multiple seizure types commonly coexist in the same child over time, which complicates both classification and treatment. Longitudinal documentation of seizure semiology alongside EEG, as this study provides, helps distinguish genuine seizure-type evolution from variable descriptions of the same events.

The developmental findings round out the electroclinical picture. CDKL5 deficiency disorder causes severe global developmental impairment, and the study's paired developmental assessments show how motor and visual skills plateau or regress as the electrographic abnormalities deepen. For clinicians counseling families, the paired EEG–developmental trajectory offers a more concrete prognostic frame than seizure counts alone. It also underscores why early diagnosis matters: the window in which intervention — seizure control, physiotherapy, visual support — can influence developmental trajectory is early, and an EEG that still looks benign should not delay genetic workup.

The findings are observational and human, derived from a diagnosed cohort rather than an intervention trial, so they characterize the natural electroclinical course rather than test a therapy. That limitation is inherent to rare-disease research. The study's value lies in the timeline it establishes.

Future work will likely build on this longitudinal characterization to define EEG-based markers that predict developmental outcome and to evaluate whether earlier, genotype-informed treatment alters the trajectory the study so carefully documents.